Vaxzevria highly effective at preventing COVID-19 severe outcomes and death as booster

12 December 2022

Developed by the UK’s AstraZeneca (LSE: AZN) in collaboration with scientists at the University of Oxford, Vaxzevria (ChAdOx1-S [Recombinant]) was one of the first COVID-19 vaccines to come on the market, but it has been far less successful than the mega money-spinners such as Pfizer (NYSE: PFE), BioNTech’s (Nasdaq: BNTX) Comirnaty and Moderna’s (Nasdaq: MRNA) Spikevax, not to mention that it has been sold at cost and has never been approved in the vast US market.

Vaxzevria booked sales of just $4 billion in 2021 and $1.6 billion in the first six months of 2022

However, today AstraZeneca announced that Vaxzervria was highly effective at preventing Omicron-related COVID-19 severe outcomes or death when used as a first booster, irrespective of the type of vaccines previously given, with an 89% relative risk reduction.

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK